By Lizzy McLellan | January 4, 2018
Will the Trump administration's policy change on marijuana put a chill on law firms' slow embrace of cannabis clients?
By Lizzy McLellan | November 13, 2017
Fast-growing Ballard Spahr added white-collar veteran R. Stephen Stigall.
By Tom McParland | October 20, 2017
The makers of Linzess hit Teva Pharmaceuticals USA with another infringement suit Friday, accusing the Pennsylvania-based generic drugmaker of mounting a late challenge to a patent for the popular constipation drug.
By Kristen Rasmussen | National Law Journal | October 18, 2017
Rep. Thomas Marino, R-Pennsylvania, withdrew his name for consideration as President Trump's drug czar, two days after a bombshell from The Washington Post/60 Minutes report about the congressman's role as chief advocate for a 2016 federal law that weakened the U.S. Drug Enforcement Administration's control over opioid distributors. Here are a few things to know about the man at the center of the investigation.
By Alexa Woronowicz | September 29, 2017
Finding no "true conflict" between Pennsylvania law and North Carolina law as applied to plaintiff's negligent design defect and strict liability design claims arising from his use of Risperdal®, the court applied Pennsylvania law under the state's choice of law methodology and found the claims to be precluded. The court asked the appellate court to affirm its order granting the moving defendants summary judgment.
By Zack Needles | September 22, 2017
The U.S. Court of Appeals for the Third Circuit has let stand its August ruling upholding the dismissal of antitrust claims against GlaxoSmithKline.
By thelegalintelligencer | The Legal Intelligencer | September 22, 2017
Class certification denied where plaintiffs failed to satisfy numerosity requirement, as joinder of the proposed class members was not impractical due to cost and resource sharing through joinder mitigating the financial and logistical barriers to joinder. Motion for class certification denied.
By Max Mitchell | September 20, 2017
Pharmaceutical giant Pfizer has sued rival Johnson & Johnson over claims the company forced health care providers and insurers into exclusionary contracts aimed at blocking a competing autoimmune medication Pfizer recently introduced into the market.
By Max Mitchell | September 18, 2017
The makers of the testosterone therapy AndroGel could not have prevailed on patent infringement actions they filed against a generic drug maker over the medication, a federal judge has ruled. The decision is a win for the Federal Trade Commission, which is contending that the drugmakers only filed the patent actions to delay a generic form of the drug from entering the market.
By Max Mitchell | September 14, 2017
A Philadelphia jury handed up a $57.1 million verdict against Johnson & Johnson subsidiary Ethicon after a trial over allegations that its transvaginal mesh product was defective.
Presented by BigVoodoo
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Celebrate outstanding achievement in law firms, chambers, in-house legal departments and alternative business structures.
We are seeking an associate to join our Employee Benefits practice. Candidates should have three to six years of employee benefits experienc...
Associate attorney position at NJ Immigration Law firm: Leschak & Associates, LLC, based in Freehold, NJ, is looking for a full time ass...
Duane Morris LLP has an immediate opening for a senior level, highly motivated litigation associate to join its dynamic and growing Employme...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS